As part of our mission to address key limitations of current oligonucleotide approaches, we are committed to translating the advances enabled by ESiNAR-X® into new therapeutic opportunities.
Every therapeutic program is powered by ESiNAR-X®. Select any molecule to see what it targets.
Each program progresses through defined development stages, from target selection through preclinical studies to clinical development.
Our lead program ASC1R is entering Phase 1 clinical development, while further candidates advance through various stages of preclinical research.
Reduces target RNA levels by 99% within 10 days and decreases leukemic cell burden by 50% over the same period.
Read more →
Reduces viral RNA levels by more than 98% after a single dose.
Read more →
Targeting a key mediator of renal fibrosis, finishing late-stage preclinical validation.
Read more →We welcome collaborations and licensing discussions to expand our oligonucleotide therapies into new markets.